A randomized, controlled trial of everolimus‐based dual immunosuppression versus standard of care in de novo kidney transplant recipients

Summary Kidney transplant recipients receiving calcineurin inhibitor‐based immunosuppression incur increased long‐term risks of cancer and kidney fibrosis. Switch to mammalian target of rapamycin (mTOR) inhibitors may reduce these risks. Steroid or Cyclosporin Removal After Transplant using Everolim...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Transplant international 2014-03, Vol.27 (3), p.302-311
Hauptverfasser:	Chadban, Steven J., Eris, Josette Marie, Kanellis, John, Pilmore, Helen, Lee, Po Chang, Lim, Soo Kun, Woodcock, Chad, Kurstjens, Nicol, Russ, Graeme
Format:	Artikel
Sprache:	eng
Schlagworte:	Adrenal Cortex Hormones - administration & dosage Adult Aged Calcineurin Inhibitors - administration & dosage Clinical Research cyclosporin Cyclosporine - administration & dosage Everolimus Female Glomerular Filtration Rate Humans Immunosuppression - adverse effects Immunosuppression - methods Immunosuppressive Agents - administration & dosage Immunosuppressive Agents - therapeutic use Kidney Transplantation Male mammalian target of rapamycin Middle Aged Mycophenolic Acid - administration & dosage Prospective Studies Sirolimus - administration & dosage Sirolimus - analogs & derivatives Sirolimus - therapeutic use Standard of Care steroids TOR Serine-Threonine Kinases - antagonists & inhibitors Transplantation Immunology Treatment Outcome Young Adult
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!